NuVasive(R) Announces Global Launch of MAS(R) PLIF

NuVasive(R) Announces Global Launch of MAS(R) PLIF 
SAN DIEGO, CA -- (Marketwired) -- 05/31/13 --  NuVasive, Inc.
(NASDAQ: NUVA), a medical device company focused on developing
minimally disruptive surgical products and procedures for the spine,
is excited to announce the global launch of its Maximum Access
Surgery Posterior Lumbar Interbody Fusion (MAS(R) PLIF) procedure. 
Initially released in a limited launch around the United States, the
NuVasive MAS PLIF is now available for patients and surgeons in
Australia, Switzerland, Italy, Germany, and the United Kingdom. 
Surgeons who played a key role in the innovation and development of
the procedure have been instrumental in training other surgeons in
both of the NuVasive San Diego and New Jersey state-of-the-art
cadaveric labs. 
"MAS PLIF is a unique procedure that offers truly reproducible
results that embrace traditional surgical principles," said Nitin
Khanna, M.D. "The beauty is in the simplicity of the system, which
all surgeons can implement in their practice."  
The minimally disruptive procedure was uniquely developed by surgeon
design and product development teams to cohesively output the access,
fixation, interbody, graft delivery, and neuromonitoring components
specific to the procedure. 
"The integration effort is undeniable in the final output of the
system," said Gurvinder Deol, M.D. "Every nuance, from the unique
retractor blades, the laterally placed interbody cages, the modular
screw option, and the insulated pedicle prep instruments make for a
seamless, safe, and reproducible procedure." 
MAS(R) PLIF is designed to eliminate the need to retract back muscles
as wide laterally as a traditional, or "open," PLIF, therefore
requiring a smaller incision. By minimizing the amount of muscle
disruption, the procedure is intended to help reduce postoperative
approach-related muscle pain and to enable a faster recovery for the
patient. 
For NuVasive press materials please visit:
http://www.nuvasive.com/about-us/newsroom/  
About NuVasive 
NuVasive is an innovative global medical device company that is
changing spine surgery with minimally disruptive surgical products
and procedurally integrated solutions for the spine. The Company is
the 4th largest player in the $8.2 billion global spine market. 
NuVasive offers a comprehensive spine portfolio of over 80 unique
products developed to improve spine surgery and patient outcomes. The
Company's principal procedural solution is its Maximum Access
Surgery, or MAS(R) platform for lateral spine fusion. MAS provides
safe, reproducible, and clinically proven outcomes, and is a highly
differentiated solution with fully integrated neuromonitoring,
customizable exposure, and a broad offering of application-specific
implants and fixation devices designed to address a variety of
pathologies.  
Having pioneered the lateral approach to spine fusion, NuVasive
continues to be at the forefront of the spine industry's shift toward
less invasive solutions. The Company places a large focus on clinical
research and support of the Society of Lateral Access Surgery, or
SOLAS(R), to expand the body of clinical evidence in support of
NuVasive's minimally disruptive solutions and to drive adoption of
its techniques. The Company's dedication to innovation continues to
spawn game changing technology such as the PCM(R) motion preserving
disc for the cervical spine, XLIF(R) Corpectomy for tumor and trauma,
and Armada(R), which treats adult degenerative scoliosis in a less
invasive fashion. The Company has also developed procedural solutions
that completely redefine and improve upon traditional procedures like
TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are
increasingly being adopted internationally, as the Company lays the
groundwork to continue growing as a global business and to offer
industry-leading, Absolutely Responsive customer service to surgeons
world-wide. NuVasive is focused on becoming a $1 Billion
Start-Up(TM); taking market share by maintaining a commitment to
Superior Clinical Outcomes, Speed of Innovation(R), and Absolute
Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to those
risks and uncertainties more fully described in NuVasive's press
releases and periodic filings with the Securities and Exchange
Commission. NuVasive's public filings with the Securities and
Exchange Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect events
or circumstances arising after the date on which it was made. 
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2324810 
Investor Contact:
Tina Jacobsen
NuVasive, Inc.
858-320-5215
investorrelations@nuvasive.com 
Media Contact:
Nicole Collins
NuVasive, Inc.
858-909-1907
media@nuvasive.com 
 
 
Press spacebar to pause and continue. Press esc to stop.